The close relationship between gastric cancer (GC) and type 2 diabetes mellitus (T2DM) has garnered significant attention. On one hand, T2DM may play a role in the development and progression of GC, correlating with poor patient outcomes. On the other hand, after radical surgery for GC, T2DM can be effectively managed, potentially improving tumor prognosis. In recent years, bariatric and metabolic surgery (BMS) has revolutionized T2DM treatment for obese and overweight patients. Comparative analyses reveal similarities between surgical approaches for gastric cancer and BMS, leading to the emergence of the onco-metabolic surgery (OMS) concept, which suggests that radical tumor resection and T2DM remission in GC patients can be potentially achieved through a single procedure. However, there are notable differences between OMS and BMS, including target populations, surgical details, and perioperative management. Therefore, optimizing the application of the OMS concept in GC patients holds significant clinical importance. This article provides a review to facilitate the better implementation of this concept in practice.
胃癌与2型糖尿病（T2DM）的密切关系尤其引发关注，一方面，T2DM可能参与胃癌的发生发展，与患者不良预后相关；另一方面，胃癌患者接受根治性外科手术后，其T2DM也能得到较好控制，并有望改善肿瘤预后。近些年，减重代谢手术（BMS）为肥胖和超重患者T2DM治疗带来划时代的变革。比较发现，胃癌外科术式与BMS存在诸多相似之处，肿瘤代谢手术（OMS）理念因此出现，即外科医生有望通过一次手术，同时实现胃癌患者的肿瘤根治和T2DM的缓解。然而，OMS与BMS又有着诸多不同，包括适用人群、手术细节和围手术期管理等。因此，如何优化OMS理念在胃癌患者中的应用，临床意义重大。本文将对此做一综述，以期更好推行这一理念的实践。.